For example, could BPC-157 affect blood pressure, or interact with medications, or alter blood sugar levels
2 In the REIMAGINE 3 trial, the most commonly reported AEs were GI-related, occurring in 51/90 (57%) participants in the CagriSema 2.4 mg/2.4 mg group, 42/93 (45%) participants in the CagriSema 1 mg/1 mg group, and 21/91 (23%) participants in the placebo group
AOD-9604 (Anti-Obesity Drug 9604) Description: A fat-burning peptide that stimulates the breakdown of stored fat while preventing new fat deposits, mimicking the fat-loss effects of growth hormone
13 , 2026
Much of the online conversation focuses on whether BPC-157 works
Development of a self-assembled nanoparticle formulation of orlistat, Nano-ORL, with increased cytotoxicity against human tumor cell lines